Department of Surgery and Transplantation, University Hospital Zurich, Zurich, Switzerland.
Department of Surgery and Transplantation, University Hospital Zurich, Zurich, Switzerland.
Lancet Gastroenterol Hepatol. 2017 Jul;2(7):531-537. doi: 10.1016/S2468-1253(16)30208-4. Epub 2017 Mar 28.
Liver transplantation has improved dramatically over the past three decades, mainly as a result of advances in surgical techniques and management of post-transplant complications. The focus has now turned towards rescuing additional organs in the face of scarce organ supply, or prevention of long-term toxicity associated with immunosuppression. The liver appears to be privileged in terms of immune tolerance, with a low incidence of antibody-mediated rejection, which is in sharp contrast to other solid organ transplants, such as kidney, lung, and heart transplants. However, tolerogenic processes remain poorly understood, and strategies for complete drug withdrawal should be selected carefully to avoid graft rejection. In this Review, we summarise the current understanding of liver-specific immune responses and provide an outlook on future approaches.
在过去的三十年中,肝移植取得了显著进展,主要得益于手术技术的进步和移植后并发症的处理。现在的重点已经转向在器官供应稀缺的情况下抢救更多的器官,或预防与免疫抑制相关的长期毒性。肝脏在免疫耐受方面似乎具有优势,抗体介导的排斥反应发生率较低,这与其他实体器官移植(如肾、肺和心脏移植)形成鲜明对比。然而,免疫耐受的过程仍知之甚少,并且应谨慎选择完全停药的策略,以避免移植物排斥。在这篇综述中,我们总结了目前对肝脏特异性免疫反应的理解,并对未来的方法进行了展望。